Drug Trial Radar · NCT00506441
A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia
Last checked: Nov 20, 2026Latest source record: Jan 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
245
Actual
Start
Sep 2007
Primary completion
Sep 2009
Study completion Sep 2009
Sponsor
- Lead sponsor
- Tanabe Pharma CorporationIndustry
- Sponsor type
- Industry
- First posted
- Jul 25, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase III multi-centre study in three periods: the first period is a phosphate binder washout for 4 weeks, the second period is an open-label, flexible dose titration, the third period is a placebo-controlled withdrawal comparing MCI-196 with placebo for 4 weeks.
Conditions
- Chronic Kidney Disease
- Dialysis
- Hyperphosphatemia
Interventions
MCI-196Drug
3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose (Open-label) and 4 weeks of double blind
PlaceboDrug
3g to 15g/day (3 times a day), Tablet, 4 weeks of double blind
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Change in Serum Phosphorus From Week 12 to Week 16Time frame: 4 weeks (Week 12 to Week 16)
Locations
39 sites in 2 countries. Site status is shown where the registry gives one.
Site not named
Glendale, Arizona
Site not named
Tempe, Arizona
Site not named
Hot Springs, Arkansas
Site not named
Paragould, Arkansas
Site not named
Pine Bluff, Arkansas
Site not named
Fountain Valley, California
Site not named
La Mesa, California
Site not named
Long Beach, California
Site not named
Lynwood, California
Site not named
Orange, California
Site not named
San Diego, California
Site not named
Whittier, California
Site not named
Brandon, Florida
Site not named
Hudson, Florida
Site not named
Lauderdale Lakes, Florida
Site not named
Tampa, Florida
Site not named
Augusta, Georgia
Site not named
Decatur, Georgia
Site not named
Macon, Georgia
Site not named
Evanston, Illinois
Site not named
Evergreen Park, Illinois
Site not named
Fort Wayne, Indiana
Site not named
Shreveport, Louisiana
Site not named
Springfield, Massachusetts
Site not named
Eatontown, New Jersey
Site not named
Flushing, New York
Site not named
Springfield Gardens, New York
Site not named
Allentown, Pennsylvania
Site not named
Lewistown, Pennsylvania
Site not named
Philadelphia, Pennsylvania
Site not named
Columbia, South Carolina
Site not named
Orangeburg, South Carolina
Site not named
Sumter, South Carolina
Site not named
San Antonio, Texas
Site not named
Alexandria, Virginia
Site not named
Portsmouth, Virginia
Site not named
Richmond, Virginia
Site not named
West Allis, Wisconsin
Site not named
San Juan, Puerto Rico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.